Literature DB >> 17093977

Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.

Ho-Joo Lee1, Jagadeesh S Rao, Renee N Ertley, Lisa Chang, Stanley I Rapoport, Richard P Bazinet.   

Abstract

RATIONALE: Fluoxetine is used to treat unipolar depression and is thought to act by increasing the concentration of serotonin (5-HT) in the synaptic cleft, leading to increased serotonin signaling. The 5-HT(2A/2C) receptor subtypes are coupled to a phospholipase A(2) (PLA(2)). We hypothesized that chronic fluoxetine would increase the brain activity of PLA(2) and the turnover rate of arachidonic acid (AA) in phospholipids of the unanesthetized rat.
MATERIALS AND METHODS: To test this hypothesis, rats were administered fluoxetine (10 mg/kg) or vehicle intraperitoneally daily for 21 days. In the unanesthetized rat, [1-(14)C]AA was infused intravenously and arterial blood plasma was sampled until the animal was killed at 5 min and its brain was subjected to chemical, radiotracer, or enzyme analysis.
RESULTS: Using equations from our fatty acid model, we found that chronic fluoxetine compared with vehicle increased the turnover rate of AA within several brain phospholipids by 75-86%. The activity and protein levels of brain cytosolic PLA(2) (cPLA(2)) but not of secretory or calcium-independent PLA(2) were increased in rats administered fluoxetine. In a separate group of animals that received chronic fluoxetine followed by a 3-day saline washout, the turnover of AA and activity and protein levels of cPLA(2) were not significantly different from controls. The protein levels of cyclooxygenases 1 and 2 as well as the concentration of prostaglandin E(2) in rats chronically administered fluoxetine did not differ significantly from controls.
CONCLUSION: The results support the hypothesis that fluoxetine increases the cPLA(2)-mediated turnover of AA within brain phospholipids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093977     DOI: 10.1007/s00213-006-0582-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  90 in total

1.  Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus.

Authors:  K J Damjanoska; L D Van de Kar; G H Kindel; Y Zhang; D N D'Souza; F Garcia; G Battaglia; N A Muma
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

Review 2.  Resolution of inflammation: the beginning programs the end.

Authors:  Charles N Serhan; John Savill
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

Review 3.  Phospholipid fatty acid remodeling in mammalian cells.

Authors:  J I MacDonald; H Sprecher
Journal:  Biochim Biophys Acta       Date:  1991-07-09

4.  Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.

Authors:  M C Chang; J M Bell; A D Purdon; E G Chikhale; E Grange
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

5.  5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter.

Authors:  Ying Qu; Nelly Villacreses; Dennis L Murphy; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2005-04-15       Impact factor: 4.530

6.  Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI).

Authors:  Ying Qu; Lisa Chang; Justin Klaff; Andrea Balbo; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2002-06-05       Impact factor: 7.853

Review 7.  Lipid signaling in neural plasticity, brain repair, and neuroprotection.

Authors:  Nicolas G Bazan
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

8.  Cytosolic phospholipase A2 gene expression in rat mesangial cells is regulated post-transcriptionally.

Authors:  A Tay; P Maxwell; Z G Li; H Goldberg; K Skorecki
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

9.  Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

10.  Prostaglandin receptor site: evidence for an essential role in the action of luteinizing hormone.

Authors:  F A Kuehl; J L Humes; J Tarnoff; V J Cirillo; E A Ham
Journal:  Science       Date:  1970-08-28       Impact factor: 47.728

View more
  20 in total

1.  Investigation of postmortem brain polyunsaturated fatty acid composition in psychiatric disorders: limitations, challenges, and future directions.

Authors:  Robert K McNamara; Ronald Jandacek
Journal:  J Psychiatr Res       Date:  2010-05-26       Impact factor: 4.791

2.  Knocking out the dopamine reuptake transporter (DAT) does not change the baseline brain arachidonic acid signal in the mouse.

Authors:  Epolia Ramadan; Lisa Chang; Mei Chen; Kaizong Ma; F Scott Hall; George R Uhl; Stanley I Rapoport; Mireille Basselin
Journal:  Int J Neurosci       Date:  2012-03-26       Impact factor: 2.292

3.  Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.

Authors:  Yewon Cheon; Jee-Young Park; Hiren R Modi; Hyung-Wook Kim; Ho-Joo Lee; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport
Journal:  J Neurochem       Date:  2011-09-20       Impact factor: 5.372

Review 4.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

Review 5.  Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Authors:  Stanley I Rapoport
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

6.  Brain phospholipid arachidonic acid half-lives are not altered following 15 weeks of N-3 polyunsaturated fatty acid adequate or deprived diet.

Authors:  Joshua T Green; Zhen Liu; Richard P Bazinet
Journal:  J Lipid Res       Date:  2009-08-06       Impact factor: 5.922

7.  Transient postnatal fluoxetine leads to decreased brain arachidonic acid metabolism and cytochrome P450 4A in adult mice.

Authors:  Epolia Ramadan; Helene Blanchard; Yewon Cheon; Meredith A Fox; Lisa Chang; Mei Chen; Kaizong Ma; Stanley I Rapoport; Mireille Basselin
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-01-30       Impact factor: 4.006

Review 8.  Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.

Authors:  Joanne J Liu; Pnina Green; J John Mann; Stanley I Rapoport; M Elizabeth Sublette
Journal:  Brain Res       Date:  2014-12-08       Impact factor: 3.252

9.  Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice.

Authors:  Mireille Basselin; Meredith A Fox; Lisa Chang; Jane M Bell; Dede Greenstein; Mei Chen; Dennis L Murphy; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

10.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.